David Wotherspoon

David Wotherspoon is a highly experienced scientific consultant currently employed at Resilient Collective since October 2024. Prior to this role, David held positions at Bastion Therapeutics as a Senior Scientist leading projects in Human Treg cell therapy production and vector manufacture, and as Scientist II developing Treg therapies for autoimmune disorders. Previous experience includes working at Takeda as Scientist I, focusing on genetically engineered GammaDelta T cell therapies, and as a Research Associate Scientist. David's academic qualifications include a PhD in Haemato-Oncology from Queen Mary University of London, where research centered on the m6A mRNA reader YTHDF2, alongside an MBIOL in Biological Sciences from the University of Leeds. Early career experiences included internships and work placements at ICON plc, Dstl, and various research roles at Barts Cancer Institute and the University of Edinburgh.